LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Lipocine Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$1.53−0.03 (-1.92%)
Close on Oct 19, 2026
- Market cap
- $12.57M
- P/E (TTM)
- –
- Dividend yield
- –
Lipocine Inc. revenue by segment
By business segment
By product or service
| Revenue | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 21 | Q3 21 | Q3 18 | Q2 18 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License [Member] | $1.00M | $0 | $500.00K | – | – | – | – | – | $10.95M | $54.99K | – | – | 87.3% | – |
| License and Service [Member] | – | – | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
By region
From the segment and revenue-disaggregation notes of Lipocine's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.